Lipid-lowering effects of colesevelam HCl in combination with ezetimibe

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2191-2200

  Bays, Harold ^a   Rhyne, James ^b   Abby, Stacey ^c   Lai, Yu Ling ^c   Jones, Michael ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Lipid Center   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

Bile acid; Cholesterol; Colesevelam HCl; Ezetimibe; Lipid; Myopathy; Non statin

Indexed keywords

APOLIPOPROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; COLESEVELAM; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ALLYLAMINE; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 33751238477     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148436     Document Type: Conference Paper

References (27)

1. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease [A joint statement by the American Heart Association on and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association]. Circulation 1990;81:1721-33
2. Jacobson TA. Clinical context: current concepts of coronary heart disease management. Am J Med 2001;110(Suppl 6A):3S-11S
3. Stein EA. Identification and treatment of individuals at high risk of coronary heart disease. Am J Med 2002;112(Suppl 8A):3S-9
4. NCEP-ATP. NCEP-ATP III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert panel report. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002 September. Report No.: NIH Publication No. 02-5215. 2002
5. Kwiterovich PO. A review of lipid-modifying drugs used alone and in combination. Adv Studies Med 2005;5:475-91
6. Crestor [prescribing information]. Wilmington, DE: AstraZeneca; 2005
7. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006;97:S6-S26
8. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795-7
9. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53-S58
10. Myant NB, Mitropoulos KA. Cholesterol 7 alpha-hydroxylase. J Lipid Res 1977;18:135-53
11. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-90
12. Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints 2000;41:708-9
13. WelChol [prescribing information]. Parsippany (NJ): Daiichi Sankyo, Inc; 2003
14. Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257-73
15. Anon. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-64
16. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type Coronary Intervention Study. Circulation 1984;69:313-24
17. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900
18. Insull Jr W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971-82
19. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002;11:1587-604
20. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124-8
21. Zetia [prescribing information]. North Wales (PA): Merck/Schering-Plough Pharmaceutials; 2005
22. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363-8
23. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
24. FDA. United States Food and Drug Administration, Code of Federal Regulations Title 21, Volume 5, Section 312.32, IND Safety Reports, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. 2005
25. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
26. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205
27. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306-10